Koboteh and colleagues [27] reported that the BSI and Gleason scores were independent predictive factors of survival in men with a high risk of prostate cancer who were treated by androgen ablation therapy, although clinical stage and pre-treatment PSA levels were not prognostic factors. The gene discussed is KLK3; the disease is prostate cancer.